NEW YORK (GenomeWeb News) – Horizon Discovery said today that it has launched a subsidiary called Horizon Dx to support the development, approval, and sale of companion diagnostics, initially in the area of cancer.

Horizon Dx, or HDx, will use Horizon Discovery's panel of more than 175 X-MAN human isogenic cell models that recapitulate drug sensitivity and resistance mechanisms in cancer patients. These cell models use a proprietary gene-engineering technology called GENESIS that enables rapid and precise alteration of any endogenous gene loci in human cells.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The president of France's National Research Agency has resigned, according to Nature News.

A senator wants a "right-to-try" provision in the US Food and Drug Administration funding bill, but an ethicist says at Stat News that it would undermine the role of clinical trials.

In PNAS this week: red algae Porphyra umbicalis genome, deep neural network model for sequencing peptides, and more.

The Guardian's Barbara Ellen has tried out some DNA testing services to see whether they provide valuable information.